Arrowstreet Capital Limited Partnership Raises Stock Position in Relx Plc (NYSE:RELX)

Arrowstreet Capital Limited Partnership lifted its position in shares of Relx Plc (NYSE:RELX) by 50.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,968,739 shares of the technology company’s stock after acquiring an additional 658,655 shares during the quarter. Arrowstreet Capital Limited Partnership owned 0.11% of Relx worth $89,420,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of RELX. Natixis Advisors LLC raised its position in Relx by 2.8% during the fourth quarter. Natixis Advisors LLC now owns 1,202,592 shares of the technology company’s stock worth $54,622,000 after acquiring an additional 32,739 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Relx during the 4th quarter worth approximately $44,516,000. JPMorgan Chase & Co. raised its position in shares of Relx by 14.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 826,481 shares of the technology company’s stock worth $39,225,000 after purchasing an additional 104,999 shares during the last quarter. Reynders McVeigh Capital Management LLC lifted its stake in Relx by 31.8% in the 3rd quarter. Reynders McVeigh Capital Management LLC now owns 495,004 shares of the technology company’s stock valued at $23,493,000 after buying an additional 119,405 shares in the last quarter. Finally, American Century Companies Inc. grew its holdings in Relx by 5.1% during the 4th quarter. American Century Companies Inc. now owns 405,100 shares of the technology company’s stock valued at $18,400,000 after buying an additional 19,728 shares during the last quarter. Institutional investors and hedge funds own 15.02% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Redburn Atlantic started coverage on Relx in a research note on Wednesday, January 8th. They set a “buy” rating on the stock. The Goldman Sachs Group started coverage on shares of Relx in a research report on Wednesday, March 26th. They set a “buy” rating on the stock. StockNews.com downgraded Relx from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Finally, Barclays raised Relx from an “equal weight” rating to an “overweight” rating in a research report on Friday, March 14th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy”.

Relx Price Performance

RELX opened at $50.43 on Tuesday. Relx Plc has a 1 year low of $40.25 and a 1 year high of $51.99. The company’s 50 day simple moving average is $49.53 and its 200 day simple moving average is $47.84. The stock has a market capitalization of $93.61 billion, a PE ratio of 27.12, a P/E/G ratio of 2.73 and a beta of 0.90. The company has a debt-to-equity ratio of 1.46, a quick ratio of 0.47 and a current ratio of 0.52.

Relx Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Wednesday, June 25th. Shareholders of record on Friday, May 9th will be issued a $0.5586 dividend. This represents a dividend yield of 1.6%. The ex-dividend date is Friday, May 9th. This is a positive change from Relx’s previous semi-annual dividend of $0.23. Relx’s dividend payout ratio (DPR) is 59.68%.

Relx Profile

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.